Ulinastatin - Techpool
Alternative Names: Techpool RoanLatest Information Update: 03 Sep 2024
At a glance
- Originator Techpool Bio-Pharma
- Class Anti-inflammatories; Cytoprotectives; Furans; Glycoproteins; Uroprotectives
- Mechanism of Action Serine protease inhibitors; Trypsin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Pancreatitis; Vascular disorders
- No development reported Severe acute respiratory syndrome
Most Recent Events
- 28 Aug 2024 Guangdong Techpool Bio-pharma plans a phase III IMPROVING trial for Sepsis (In Neonates, In Infants, In Children, In adolescents) in China (IV) (ISRCTN15982148)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Severe acute respiratory syndrome(In volunteers) in China (IV, Injection)
- 08 Jun 2018 Chemical structure information added